Dr Reddy’s Laboratories failed to cheer the market despite June quarter net profit doubling. Analysts see concern over the US business and pressure on operating performance as key drags. These concerns have prompted traders to build bearish bets on the stock. Chandan Taparia, derivative analyst at Motilal Oswal, said the weakness could continue and the stock could drift down to Rs 3,950.
Sebi launches new verification agency to crack down on mis-selling
Sebi has launched the Past Risk and Return Verification Agency (PaRRVA) to combat mis-selling of investment products. This tech-driven system, linking credit rating agencies and
December 9, 2025